Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci
- PMID: 25713336
- PMCID: PMC4402340
- DOI: 10.1093/aje/kwu290
Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci
Abstract
Autoimmune conditions and immune system-related genetic variations are associated with risk of non-Hodgkin lymphoma (NHL). In a pooled analysis of 8,692 NHL cases and 9,260 controls from 14 studies (1988-2007) within the International Lymphoma Epidemiology Consortium, we evaluated the interaction between immune system genetic variants and autoimmune conditions in NHL risk. We evaluated the immunity-related single nucleotide polymorphisms rs1800629 (tumor necrosis factor gene (TNF) G308A), rs1800890 (interleukin-10 gene (IL10) T3575A), rs6457327 (human leukocyte antigen gene (HLA) class I), rs10484561 (HLA class II), and rs2647012 (HLA class II)) and categorized autoimmune conditions as primarily mediated by B-cell or T-cell responses. We constructed unconditional logistic regression models to measure associations between autoimmune conditions and NHL with stratification by genotype. Autoimmune conditions mediated by B-cell responses were associated with increased NHL risk, specifically diffuse large B-cell lymphoma (odds ratio (OR) = 3.11, 95% confidence interval (CI): 2.25, 4.30) and marginal zone lymphoma (OR = 5.80, 95% CI: 3.82, 8.80); those mediated by T-cell responses were associated with peripheral T-cell lymphoma (OR = 2.14, 95% CI: 1.35, 3.38). In the presence of the rs1800629 AG/AA genotype, B-cell-mediated autoimmune conditions increased NHL risk (OR = 3.27, 95% CI: 2.07, 5.16; P-interaction = 0.03) in comparison with the GG genotype (OR = 1.82, 95% CI: 1.31, 2.53). This interaction was consistent across major B-cell NHL subtypes, including marginal zone lymphoma (P-interaction = 0.02) and follicular lymphoma (P-interaction = 0.04).
Keywords: autoimmune conditions; environment; genetics; human leukocyte antigen; interaction; lymphoma, non-Hodgkin; tumor necrosis factor.
© The Author 2015. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
References
-
- Roman E, Smith AG. Epidemiology of lymphomas. Histopathology. 2011;58(1):4–14. - PubMed
-
- Hartge P, Wang SS, Bracci PM, et al. Non-Hodgkin Lymphoma. 3rd ed. New York, NY: Oxford University Press; 2006.
-
- Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98(1):51–60. - PubMed
-
- Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2069–2077. - PubMed
-
- Baecklund E, Smedby KE, Sutton LA, et al. Lymphoma development in patients with autoimmune and inflammatory disorders—what are the driving forces? Semin Cancer Biol. 2014;24:61–70. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA89745/CA/NCI NIH HHS/United States
- CA033572/CA/NCI NIH HHS/United States
- CAPMC/ CIHR/Canada
- CA92153/CA/NCI NIH HHS/United States
- CA87014/CA/NCI NIH HHS/United States
- N01 CO012400/CA/NCI NIH HHS/United States
- R01 CA092153/CA/NCI NIH HHS/United States
- R01 CA087014/CA/NCI NIH HHS/United States
- R01 CA045614/CA/NCI NIH HHS/United States
- N01-CO-12400/CO/NCI NIH HHS/United States
- R03 CA089745/CA/NCI NIH HHS/United States
- R01 CA154643/CA/NCI NIH HHS/United States
- R01 CA062006/CA/NCI NIH HHS/United States
- CA17955801/CA/NCI NIH HHS/United States
- P30 CA033572/CA/NCI NIH HHS/United States
- R03 CA179558/CA/NCI NIH HHS/United States
- R01 CA149445/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
